ArticleTranslational cancer research2025
Establishment and characterization of two patient-derived cell lines from a patient with gallbladder carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The patient-derived primary cell line (PDC) exhibits similar biological characteristics to the original tumor tissue, and is a unique translational medicine tool for studying the growth, differentiation, metastasis and drug sensitivity of malignant tumor cells. However, due to the limited number of PDC models of gallbladder cancer (GBC) and the high genetic heterogeneity of GBC, it is necessary to establish PDC models representing different types of GBC patients. The aim of this study is to establish GBC PDCs and characterize their biological features, which can be used as Methods: Two PDCs were developed from one patient with GBC (JXQ-3D-1404R1 and JXQ-3D-1404R2). The two cancer cell lines were characterized with respect to phenotypic, molecular, and functional properties and drug sensitivity. Results: The JXQ-3D-1404R1 and JXQ-3D-1404R2 cell lines showed multiple cell shapes and characteristic epithelial morphologies with population doubling time (PDT) of approximately 19.5 and 17.5 hours, respectively. Short tandem repeat (STR) analysis confirmed the origination of the two cell lines from primary tumor tissue. JXQ-3D-1404R1 and JXQ-3D-1404R2 cell lines showed similar proliferation, migration, and colony formation properties Conclusions: Our results confirmed the validity of the JXQ-3D-1404R1 and JXQ-3D-1404R2 cell lines as representative preclinical models for the elucidation of the carcinogenesis of GBC and for pharmaceutical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.